Hannah is a DPhil student at the Centre for Medicines Discovery (CMD) and Target Discovery Institute (TDI), supervised by Dr Elena Navarro Guerrero in the Cellular High Throughput Screening group, and by Dr Emma Mead and Dr Margarida Ruas in the ARUK Oxford Drug Discovery Institute. Her research focuses on the immune system and its role in the progression of Alzheimer’s disease. Utilising the expertise in CRISPR/Cas9 screens, she is investigating the role of lipid metabolism in iPSC-derived microglia.
Prior to joining the department Hannah graduated from UCL in 2022 with an MRes in Translational Neuroscience. Her master’s project was undertaken in Professor Adrian Isaacs lab within the Dementia Research Institute, investigating genetic regulators of dipeptide protein production in the C9orf72 amyotrophic lateral sclerosis / frontotemporal dementia (ALS/FTD) using CRISPR/Cas9 technology. In 2021 she graduated from Cardiff University with a BSc in Biomedical Sciences (Physiology), where she undertook research investigating the role of autophagy in ALS/FTD during her final year.